Monocytes and macrophages utilize the class A and B scavenger receptors to recognize and perform phagocytosis of invading microbes before a pathogen-specific immune response is generated. HIV-1 Nef protein affects the innate immune system impairing oxidative burst response and phagocytic capacity of macrophages. Our data show that exogenous recombinant myristoylated Nef protein induces a marked CD36 downregulation in monocytes from Peripheral Blood Mononuclear Cells, in Monocyte-Derived Macrophages (MDMs) differentiated by cytokines and in MDMs contained in a mixed culture obtained expanding PBMCs under Human Erythroid Massive Amplification condition. Under the latter culture condition we identify three main populations after 6 days of expansion: lymphocytes (37.8614.7%), erythroblasts (46.766.1%) and MDMs (15.767.5%). The Nef addition to the cell culture significantly downregulates CD36 expression in MDMs, but not in erythroid cells. Furthermore, CD36 inhibition is highly specific since it does not modify the expression levels of other MDM markers such as CD14, CD11c, CD86, CD68, CD206, Toll-like Receptor 2 and Toll-like Receptor 4. Similar results were obtained in MDMs infected with VSV-G pseudotyped HIV-1-expressing Nef. The reduced CD36 membrane expression is associated with decrease of correspondent CD36 mRNA transcript. Furthermore, Nef-induced CD36 downregulation is linked to both impaired scavenger activity with reduced capability to take up oxidized lipoproteins and to significant decreased phagocytosis of fluorescent beads and GFP-expressing Salmonella tiphymurium. In addition we observed that Nef induces TNF-a release in MDMs. Although these data suggest a possible involvement of TNF-a in mediating Nef activity, our results exclude a possible relationship between Nef-induced TNF-a release and Nef-mediated CD36 downregulation. The present work shows that HIV-1 Nef protein may have a role in the strategies elaborated by HIV-1 to alter pathogen disease outcomes, by modulating CD36 expression in macrophages, favoring the onset of opportunistic infections in HIV-1 infected people.
Introduction
Human phagocytic cells (i.e. monocytes, macrophages and neutrophils) represent the first line of host defences against pathogens, and play a crucial role in removing apoptotic and necrotic cells, and in killing tumor cells [1] . Internalization and subsequent destruction of pathogens are key processes of innate immune response promoting antigen presentation and development of adaptive immunity. In particular, macrophages express activation surface markers and produce proinflammatory cytokines and chemokines to control pathogen spreading by recruiting peripheral lymphocytes and monocytes at the site of inflammation. Monocytes and/or macrophages may also employ PatternRecognition Receptors (PRRs) to identify highly conserved microbial structures and to internalize invading microbes before a pathogen-specific immune response has been generated.
The class B scavenger receptor CD36 is an 88-kDa cell surface transmembrane glycoprotein belonging to PRR family that comprises class A and B scavenger receptors. The receptor consists of two short intracellular domains and a large extracellular domain and shows an extensive N-glycosylation; its transcription is mainly controlled by the heterodimer PPARc/RXR (Peroxisome Proliferator-Activated Receptor c/Retinoid 6 Receptor) [2] . CD36 is widely found in different cells and tissues such as macrophages, microglia, microvascular endothelium, cardiac and skeletal muscles, adipocytes and platelets [3] . It is implicated in a wide array of normal and pathologic biological functions, including angiogenesis, atherosclerosis, inflammation, and lipid metabolism [3, 4] . CD36 was first identified as a receptor for recognizing and internalizing specific oxidized phospholipids and lipoproteins, but it also participates in the internalization of apoptotic cells, bacterial and fungal pathogens [5, 6] . As regards bacterial phagocytic function, conflicting results about the specificity of CD36 as a pattern recognition receptor of Grampositive or Gram-negative bacteria were reported [7, 8] . In this perspective, Baranova et al [9] observed phagocytosis of both Gram-negative and Gram-positive bacteria in hCD36-overexpressing transfected HeLa cells suggesting that no preference exists for their uptake.
Human Immunodeficiency Viruses (HIV-1 and HIV-2) cause Acquired Immunodeficiency Syndrome (AIDS), primarily infecting crucial cells of the immune system such as CD4 T-cells, dendritic and macrophages cells. Before the AntiRetroviral Therapy (ART) era, the role of HIV-1-infected Monocyte-Derived Macrophages (MDMs) in the development of AIDS was unclear. However, it is now evident that the occurrence of macrophagemediated diseases represents a continuous risk in HIV-1-infected individuals, even in the presence of high counts of CD4
+ T-cells. Several HIV-1-associated diseases -i.e. AIDS-Related Lymphoma (ARL), metabolic syndromes (including CardioVascular Diseases, CVDs; atherosclerosis and other lipid disorders), and HIV-Associated Dementia (HAD) -can be considered as all macrophage-mediated disorders in which Nef is an unquestioned key factor [10] . The viral regulatory protein Nef is a 27-34 kDa myristoylated protein produced exclusively by HIV and SIV (Simian Immunodeficiency Virus) and it is considered a virus component that plays a critical role in AIDS pathogenesis in HIVinfected humans [11] . Although Nef does not show catalytic activity, it influences cellular signaling pathways leading to the enhancement of viral replication, immune elusion, and enhanced survival in T-cells and macrophages [12] . At first the functions attributed to Nef were the capacity to down-modulate surface expression of the HIV-1 receptor CD4 and the Major Histocompatibility Complex class I (MHC-I) molecules. Further studies have demonstrated the involvement of Nef protein in dysregulation of HIV-1-infected macrophages functions. In addition to CD4 and MHC-I, other molecules of relevance are modulated by Nef in monocytes/macrophages, included the CCR5, one of the major HIV co-receptors. Nef can also modify signaling pathways in infected as well in non-infected macrophages when captured exogenously as a soluble factor. Other mechanisms based on cellto-cell transfer are well documented phenomena in macrophage cells as a way to deliver Nef. Indeed, infected macrophages may transfer Nef to B cells, where it would interfere with immunoglobulin class-switch recombination thus contributing to the B-cell dysfunction and humoral defect observed in HIV-1 positive subjects. Furthermore, Nef can protect the infected macrophage from cell death favoring viral production and long-standing persistence specifically inhibiting late maturating stages of autophagosomal pathway. A summary of Nef functions has been recently published by Ghiglione and Turk in a comprehensive review [13] where the Nef biology and its role in HIV pathogenesis are extensively discussed.
HIV-1 infection also compromises the functionality of phagocytic cells favoring the reactivation and development of opportunistic infections during AIDS progression. Nef protein can affect the innate immune system impairing oxidative burst response and phagocytosis in monocytes/macrophages from HIV-1 patients [14] [15] [16] . Moreover, Nef induces the secretion from primary human monocyte/macrophages of chemotactic factors like the CC-chemokines CCL2 and CCL4 [17] , which correlate with the activation of AP-1, NF-kB, STAT1 and STAT3 transcription factors [18] [19] [20] [21] [22] .
In this study we want extend our investigation on the role played by Nef in favoring opportunistic infections during AIDS progression, by clarifying the mechanism of Nef-induced impairment of bacterial pathogen phagocytosis and of other macrophage functions. We provide clear evidence that recombinant Nef (rNef) dramatically reduces the membrane expression of the scavenger receptor CD36 inhibiting oxidized lipoprotein (oxLDL) uptake and impairing Salmonella tiphymurium phagocytosis in primary human MDMs.
Materials and Methods

Ethic Statement
PBMCs (Peripheral Blood Mononuclear Cells) and LDLs utilized in this study were obtained from buffy coats and pooled fresh plasma of healthy blood donors as anonymously provided by the Immunohematology and Transfusional Center of Policlinico Umberto I, Sapienza University, Rome. All the subjects gave their written informed consent for research purposes according to the Italian law on this matter by the Transfusion Center (Legislative Decree of the Italian Ministry of Health, January 25, 2001 and published in the Official Gazette of April 3, 2001 ).
Preparation of PBMCs
PBMCs were isolated by density gradient centrifugation 400 g for 30 min at room temperature over Ficoll-Hypaque (r,1.077, Amersham Pharmacia Biotec, Uppsala, Sweden).
Ex vivo Expansion of PBMCs
Cells were incubated at 37uC in 5% CO 2 atmosphere and expanded in HEMA (Human Erythroid Massive Amplification) culture, as described by Migliaccio et al [23] . Briefly the medium was composed of IMDM (Lonza Group Ltd, Switzerland) supplemented with Fetal Bovine Serum (FBS 20% v/v, SigmaAldrich, St Louis, MO, USA), detoxified Human Serum Albumin (HSA 25%, Baxter International Inc., Deerfield, IL, USA), human-Stem Cell Factor (100 ng/mL h-SCF, Amgen, Thousand Oaks, CA), human-Erythropoietin (h-EPO 5 UI/mL, NeoRecormon, Roche Diagnostics, Penzberg, Germany), human Interleukin-3 (hIL-3, 1 ng/mL, Biosource, San Jose, CA, USA), LGlutamine (L-Glu, 200 mM, Euroclone SPA, Italy), antibiotics (10,000 units/mL Penicillin G sodium, 10,000 units/mL Strepto- Figure 1 . Nef induces downregulation of CD36 expression in human PBMC-derived monocytes. Purified monocytes evaluated for CD14 expression (data not shown) were cultured in presence 50 ng/mL of rNef/myr for three days. (A) Representative dot plots and histogram of monocytes analyzed by flow cytometry. The dot plot on the center shows the forward and side scatter of monocytes. On the left is shown the viability of cells by using SYTOX Blue dead cell stain. CD36 expression, shown in the histogram, was analyzed by using FITC-conjugated anti-CD36 antibody and the fluorescence intensity in Nef-treated (solid grey histogram) was compared to untreated (solid line) cells. Matched isotype (dotted line) was used as control of non-specific fluorescence signals. (A, below the histogram) The column bar graph represents the MFI of cells stained with matched isotype control (Ctr iso), cells stained with FITC-conjugated anti-CD36 antibody (Ctr CD36), and Nef-treated cells stained with FITCconjugated anti-CD36 antibody (Nef CD36). The results (mean 6 standard deviation) are representative of five independent experiments (*p,0.05). In B and C representative histograms of M-CSF and GM-CSF differentiated MDMs evaluated for CD14, CD4 and CD36 expression are shown. Cells were isolated by using CD14 magnetic beads (Miltenyi Biotec) and cultured in presence of human M-CSF (10 ng/mL) or GM-CSF (50 ng/mL) for 5 days before adding rNef/myr protein. CD14, CD4 and CD36 expression was analyzed by using appropriate fluorochrome-conjugated antibodies and the fluorescence intensities in Nef-treated (solid grey histogram) were compared to untreated (solid line) cells. Matched isotype (dotted line) was used as control of non-specific fluorescence signals. (B and C, below the histograms) The column bar graphs show the MFI of untreated cells (Ctr) and Neftreated cells (Nef) stained with APC-and FITC-conjugated anti-CD4 and CD36 antibodies, respectively. SYTOX Blue has been used to exclude dead cells from the analyses. The results (mean 6 standard deviation) are representative of four (MDM M-CSF) and six (MDM GM-CSF) independent experiments (*p,0.05, (**p,0.01). doi:10.1371/journal.pone.0093699.g001 , Sigma-Aldrich) and Poloxamer 188 (Pluronic F68, MW8400; Sigma-Aldrich), dexamethasone (DXM) and estradiol (ES) (each 10 26 M, Sigma-Aldrich).
The cultures were kept for up to 3 days before adding myristoylated rNef (rNef/myr) protein (50 ng/mL) or recombinant human TNF-a (10 ng/mL, PeproTech, Inc., Rock Hill, NJ, USA). Polyclonal rabbit anti-human TNF-a antibody (1 mg/mL, PeproTech, Inc.) was used in cytokine blocking experiments of Nef-treated PBMCs cultivated in HEMA culture condition. The HEMA condition without EPO was used where required by experimental procedures.
In some experiments monocytes were positively selected from total PBMCs by using CD14 magnetic beads and LS columns according to the manufacturer's instructions (Miltenyi Biotec, Bergisch Gladbach, Germany). After isolation, cells were cultured in RPMI-1640 supplemented with 10% FBS, 1% L-Glu and 1% penicillin/streptomycin for 3 days before adding rNef/myr protein. Differentiated macrophages were obtained culturing the CD14-positive monocytes isolated by using CD14 magnetic beads (Miltenyi Biotec) in the presence of recombinant human Macrophage-Colony Stimulating Factor (M-CSF, 10 ng/mL, PeproTech, Inc.) or recombinant human Granulocyte MacrophageColony Stimulating Factor (GM-CSF, 50 ng/mL, R&D System, Minneapolis, MN, USA) for 5 days before adding rNef/myr protein.
Flow Cytometry Analysis and Cell Sorting
For each sample, 1610 5 
Preparation of Recombinant Proteins
The rNef was obtained as His6-tagged fusion protein as previously described [22] . The nef gene from NL4-3 HIV-1 strain was amplified by PCR (Polymerase Chain Reaction) band cloned in frame with the His6 tag into the 59-BamHI/39-SalI sites of pQE 30 vector (Qiagen, Chatsworth, CA, USA). rNef was purified from IPTG (isopropyl b-D-thiogalactoside)-induced bacterial lysates in an 8 M urea buffer using Ni 2+ -nitrilotriacetate resin (Qiagen) according to the manufacturer's instructions. rNef was eluted with 250 mM imidazole and each fraction was analyzed by SDS/ PAGE (12% polyacrylamide). rNef-containing fractions were pooled and extensively dialyzed against 1x PBS to completely remove urea. rNef/myr proteins were prepared as previously described [24] . All recombinant protein preparations were scored as negative for the presence of bacterial endotoxin by using the Lymulus Amaebocyte Lysate assay (LAL test, BioWhittaker, Walkersville, MD, USA). In some experiments we used a recombinant myristoylated wild type HIV-1 Nef protein (myr2-210, C210S, SF2 strain, cat. PR-382) purchased from Bioscience (Jena, Germany).
To exclude possible signaling effects due to residual LPS traces in Nef preparations, experiments were performed in the presence of 10 mg/mL of polymyxin B (Sigma-Aldrich), a cationic antibiotic that binds to the lipid A portion of bacterial LPS [25] or by using rNef boiled at 100uC for 10 min.
Virus Preparation and Infection
Preparations of NL4-3 HIV-1 and its derivative defective for nef expression (DNef) pseudotyped with vesicular stomatitis virus (VSV-G) envelope glycoprotein were previously described [26] . Virus preparations were titrated by measuring HIV-1 CAp24 contents by quantitative enzyme-linked immunosorbent assay (Innotest HIV Antigen mAb, Innogenetics N.V., Ghent, Belgium). Infections of 5-day-old MDMs with pseudotyped HIV-1 were carried out by spinoculation at 400 g for 30 min at room temperature using 50 ng CAp24 equivalent of (VSV-G) HIV-1/ 10 5 cells, followed by virus adsorption for 3 h at 37uC and addition of complete medium. After 24 and 48 h the percentages of cells expressing intracytoplasmic HIV-1 Gag-related products were evaluated by FACS analysis after permeabilization with Cytofix/ Cytoperm solutions (BD biosciences) for 20 min at 4uC and labeling with 1/50 dilution of KC57-RD1 phycoerythrin (PE)-conjugated anti HIV-1 Gag CAp24 KC-57 MAb (Coulter Corp., Hialeah, FL, USA) for 1 h at 4uC. 6 cells with the RNeasy RNA extraction kit (Qiagen). Briefly, RNA was treated with recombinant DNase I (Roche, Monza, Italy) 2 times for 1 h at 37uC each time, followed by RNA clean-up procedure according to the RNeasy kit protocol. Specifically, 1 mg of the RNA was used to synthesize cDNA by employing the Reverse Transcription (RT) System kit (Promega, Madison, WI, USA). An aliquot (2 mL) of cDNA was amplified using the oligonucleotide primers derived from the CD36 cDNA sequence [27] : forward 59-TCAG-CAAATGCAAAGAAGGGAGAC-39and reverse 59-GGTTGACCTGCAGCCGTTTTG-39. The RT reaction was normalized by amplifying samples for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as house-keeping gene. CD36 primers were purchased from M-Medical-Genenco (Cornaredo, Italy) and 106QuantiTect primer Assay Mix for GAPDH was purchased by Qiagen. RT-PCR was performed by employing the SYBR Green RT-PCR kit (Qiagen) and the Applied Biosystems 7500 RealTime PCR System (Applied Biosystems, Carlsbad, CA, USA). Mix for each PCR point was: 12.5 mL of SYBR Green mix +9.5 mL of distilled water +2 mL of cDNA +1 mL primer mix (20 nM of each primer). Reactions were led at 95uC for 1 min, 60uC for 30 min 72uC for 1 min, for 40 cycles. Data were collected during every elongation step (72uC) and during final ramping (to control specificity), and analyzed by employing the Applied Biosystems 7500 SDS software (Applied Biosystems) using the 2 2DDCt method.
Plasma Low-Density Lipoprotein (LDL) Isolation
LDLs (1.019-1.063 g/mL) were isolated by density gradient ultracentrifugation in vertical rotor as previously described [28] from pooled fresh plasma of healthy volunteers provided by Transfusional Center of Policlinico Umberto I, Sapienza University, Rome, Italy. The protein content was measured by Lowry's method using BSA as standard. Neutral Red assay was used to assess the cytotoxicity of different LDL concentrations (25-200 mg/L) and 25 mg/L of protein concentration has been chosen to perform our experiments.
LDL Uptake Assay
Measurements of cell oxLDL uptake were performed with fluorescence labeled lipoproteins. One milliliter of LDL (0.5 g/L) was incubated with 12 mL 1,10-Dioctadecyl-3,3,30,30-tetramethylindo-carbocyanine perchlorate (DiI) (2 mg/mL DMSO, SigmaAldrich) and 10 mM CuSO 4 for 3 h as previously described [29] . Labeled oxLDL were extensively dialyzed with a centrifugal filter device (Millipore, Bedford, MA, USA) with a molecular weight cut-off of 5000 at 4uC, and sterilized through 0.22 mm filters (Millipore). Relative electrophoretic mobility of DiI-labeled oxLDL was 1.860.1. The degree of LDL oxidation was checked by determining the Thiobarbituric Acid Reactive Substances (TBARS) content according to Yagi [30] . The TBARS content of oxLDL was 4567 nmol malondialdehyde equivalent/mg LDL protein. DiI-oxLDL (0.025 mg/mL of culture medium) were incubated with the cells (0.5610 6 cells) for 15, 30, 60 and 120 min. Cells were resuspended in PBS containing Propidium Iodide (PI) to exclude dead cells, and then kept on ice before measuring fluorescence levels with a BD FACSAria (BD Biosciences). Fluorescence levels were normalized to cells autofluorescence.
Phagocytosis Assay
The phagocytic function was evaluated and quantified in PBMCs by following the uptake of FITC-labeled beads (Fluoresbrite BB Carboxylate Microspheres 0.50 mm, Polysciences, Inc. Eppelheim, Germany) or the internalization of Salmonella Salp572
FIS strain producing the green fluorescent protein (GFPSalmonella tiphymurium) [31] . In detail, for the assay performed with FITC-labeled beads, cells cultivated in HEMA w/o EPO were incubated for 30 min at room temperature with the beads at 1/5 ratio (cells/beads), washed and suspended in PBS. Dead cells were excluded from the analysis by Sytox Blue staining (Molecular Probes). To study the internalization of GFP-Salmonella tiphymurium cells were incubated under shacking at 37uC with bacteria for 30 min at 1/5 ratio (cells/bacteria) followed by 2 h incubation in the presence of 100 mg/mL of gentamicin (Sigma-Aldrich). Cells were washed twice in PBS and fixed in 4% paraformaldehyde (Sigma-Aldrich) in PBS. To evaluate the involvement of CD36 in the phagocytic process, cells were pre-incubated for 20 min at 37uC with mouse monoclonal anti-CD36 antibody (1 mg/10 6 cells, FA6-152, Abcam Inc., Cambridge, MA, USA) and then incubated with beads or bacteria.
The percentage of phagocytic cells was evaluated in MDMs by flow cytometry comparing fluorescence intensity of cells that incorporate particles to the cell autofluorescence.
TNF-a Release
PBMCs were cultivated at concentration of 5610 5 cells/mL for three days in HEMA condition, afterward for additional 3 days in the presence of rNef/myr. Detection of TNF-a in supernatants of HEMA-derived MDMs was performed through Human TNFalpha Quantikine ELISA Kit from R&D System following the manufacturer's recommendations.
TNF-a Bioassay
TNF-a-induced cell cytotoxicity and neutralizing activity of polyclonal rabbit anti-human TNF-a antibody were measured on WEHI 164 clone 13 cells (American Type Culture Collection, ATCC; CRL-1751) [32] by a colorimetric assay using MTT originally developed by Mosmann [33] . The WEHI 164 cell line was kept in our laboratory by propagation in RPMI 1640 (Cat. No. R-6504; Sigma-Aldrich) supplemented with 10% FBS (SigmaAldrich), 2 mM L-Glutamine (Euroclone SPA), antibiotics (10,000 units/mL Penicillin G sodium, 10,000 units/mL Streptomycin sulfate and 25 mg/mL Fungizone, PSF, Lonza Group Ltd) and were cultured at 37uC in a humidified atmosphere with 5% CO were performed at 37uC in a humidified atmosphere with 5% CO 2 air.
Statistical Analysis
Data are presented as means 6 standard deviation (S.D.). Statistical analysis was performed according to non-parametric Mann-Whitney U Test by using GraphPad Prism Software version 5.03 (GraphPad Software, Inc, La Jolla, CA, USA); p-value ,0.05 was considered significant.
Results
rNef/myr Downregulates CD36 Expression on Human Monocytes
CD36 represents a pattern recognition receptor implicated in a wide variety of normal and pathologic biological functions and mediates the uptake of various bacterial pathogens. Here we examined the effect of soluble Nef protein on human monocyte/ macrophage CD36 expression in order to identify a new viral mechanism directed to impairing phagocytosis and other macrophage functions. PBMC-derived monocytes from healthy donors were obtained as described in Materials and Methods. The purified monocytes evaluated for CD14 expression (data not shown) were cultured in the presence of 50 ng/mL of rNef/myr for additional 3 days and analyzed for CD36 expression. The flow cytometry analysis (Fig. 1A) shows a dramatic downregulation of CD36 expression. This decreased expression results highly significant only at 3 days from Nef addition to the cell culture while at 1 or 2 days the CD36 reduction appears not significant, probable as a consequence of cell culture system variability (not shown). We also evaluated CD36 modulation in MDMs by culturing CD14 positive cells for 5 days in the presence of M-CSF or GM-CSF to induce macrophage differentiation. Cells were treated with rNef/myr for additional 3 days and analyzed by flow cytometry. In figures 1B and 1C the CD14, CD4 and CD36 expression levels, measured in M-CSF and GM-CSF differentiated MDMs are shown. In these cells, 3 days treatment with rNef/myr induces a significant downregulation of CD36 expression in both culture conditions. As control of Nef activity we also evaluated the CD4, a well-known receptor whose surface expression is modulated by the HIV-1 Nef protein. As expected rNef/myr induced a significant decrease in CD4 expression in both M-CSF and GM-CSF differentiated MDMs. Interesting rNef/myr does not modify the expression levels of CD14.
rNef/myr Selectively Regulates CD36 Expression on PBMC-derived Macrophage-like Cells Cultivated in HEMA Condition
In our laboratory we developed the HEMA culture system [23] in order to obtain a massive in vitro expansion of human erythroid cells starting from total PBMCs. The population identified in culture expanded for three and six days is mainly represented by erythroblasts at different stage of differentiation, lymphocytes, and monocyte/macrophage cells [34] .
As shown in Fig. 2A , PBMCs cultivated under HEMA cell culture conditions produce three main populations with distinctive forward and side scatter profile ( Fig. 2A) (Fig. 2B) .
The PBMCs were cultivated in HEMA culture condition without EPO for three days, afterward for additional 3 days in the presence of rNef/myr and analyzed by flow cytometry for the expression of several MDM markers. As shown in Fig. 3A , the treatment with rNef/myr induces a dramatic reduction of CD36 surface expression only on MDMs. Furthermore, a significant reduction in CD4 expression is observed, as expected by the recognized activities of Nef protein. Moreover, in MDMs, rNef/ myr does not modify expression levels of CD14, CD11c, CD86, CD68 and CD206 (Fig. 3B) . Interestingly, rNef/myr treatment does not down-regulate CD36 expression in Ery cells and CD4 in Lym cells (Fig. 3A) . In synthesis, these results indicate that Nef specifically affects CD36 and CD4 expressions while does not modify the expression of other MDM markers. Furthermore, the lack of effect on CD36 and CD4 expressions in Ery and Lym cells suggests a cell specific response still to be clarified, although it is probably caused by the incapacity of erythroblasts and lymphocytes to take up the Nef protein efficiently. We also evaluated the expression of Toll-like receptor 2 and 4 (TLR2, TLR4), the type-I transmembrane proteins crucial in the recognition of pathogenassociated molecular patterns [35] and in the interaction with CD36 in inflammation and phagocytosis exerted by the innate immune system [36, 37] . Differently by CD36, TLR4 is not inhibited in cells treated with rNef/myr while the TLR2 expression significantly increases (Fig. 3C) . It should be underlined that the two different culture conditions, with or without EPO, do not affect the phenotypic profile of MDMs and, most important, the rNef/myr-dependent CD36 downregulation (not shown).
Specificity of Nef-induced CD36 Downregulation
As already described [38, 39] the bacteria cell wall component, lipopolysaccharide (LPS) induces CD36 downregulation. Thus, we evaluated specifically the effect of the LPS inhibitor polymyxin B on LPS-and Nef-mediated CD36 regulation although all the used batches of purified rNef protein preparations were tested with assay to exclude LPS contamination (see Material and Methods). As expected, induction of cell culture with LPS reduces the levels of CD36 membrane expression whereas pre-treatment with polymyxin B completely counteracts the LPS effect (Fig. 4A) . Conversely, the polymyxin B pre-treatment does not influence Nef-dependent CD36 downregulation (Fig. 4B) . These results definitely exclude a potential contribution of contaminant LPS to the Nef-mediated CD36 downregulation. 
Nef Myristoylation is Required for Stronger Activity
Asztalos et al [40] have demonstrated that recombinant myristoylated HIV-1 Nef added to the extracellular milieu of cultured human MDMs suppresses cholesterol efflux in a dose dependent manner whereas non-myristoylated Nef (rNef) is ineffective. To verify a similar behavior on CD36 expression we compared the activity of rNef/myr or rNef on mononuclear cells cultivated as above described and incubated with both the rNef proteins for three days or prolonged time (five days). As expected, rNef/myr addition on macrophage-like cells induces a dramatic reduction of CD36 expression at either, three and five days of treatment. Instead rNef was able to slightly reduce CD36 expression only at five days of treatment (Fig. 5A , C); no effect was observed on Erythroblast cells (Fig. 5B, D) , as previously reported (Fig. 3A) . The mechanism underlying the different effect between rNef/myr and rNef could be ascribed to reduced cellular uptake or failure to localize in membrane of not myristoylated Nef compromising its intracellular biological responses. It is worth noting that eight days of HEMA culture induces the expression of CD36 in all erythroblast cells (Fig. 5B, D, black histogram) [34] .
CD36 is Downregulated in MDMs Infected in vitro with Nef(+)HIV-1
The main target of this study is to assess the effects of soluble Nef on MDMs as autocrine/paracrine activities, although it is remarkable to verify, in a viral framework, the maintaining of Nef ability to downregulate CD36 expression in HIV-1 infected MDMs. For this purpose, GM-CFS differentiated MDMs at 6 days were infected with VSV-G pseudotyped HIV-1-expressing (Nef(+)-HIV-1) or not expressing the nef gene (DNef-HIV-1). The infection efficiency was controlled by estimating the levels of intracytoplasmic HIV-1 Gag-related products (HIV-1 CAp24) by flow cytometry analysis at 24 and 48 h post-infection. In Fig. 6 (right histogram) are shown the levels of infection at 48 h of both Nef(+)-HIV-1 and DNef-HIV-1 VSV-G pseudotypes and no significant differences were found between them. Similar level of HIV-1 CAp24 was observed at 24 h post-infection (not shown). CD36 expression evaluated by flow cytometry appears significantly reduced in MDMs infected with Nef(+)-HIV-1 only (Fig. 6 , center histogram and right column bar graph). As control of Nef activity we evaluated CD4 expression in the same experimental condition. Nef(+)HIV-1 induces a significant decrease in CD4 expression similarly to rNef/myr (Fig. 6 , left histogram and left column bar graph). These data appear consistent with those obtained in rNef/myr-treated cells and establish a stringent correlation between Nef and modulation of CD36 expression.
Nef-dependent Downregulation of CD36 Involves RNA Transcriptional Inhibition
We used quantitative RT-PCR to assess whether the decrease in CD36 protein levels observed in rNef/myr treated cells is linked to mRNA transcriptional inhibition. RNA was extracted from total PBMCs cultivated under HEMA w/o EPO for three days and treated with rNef/myr for additional three days, and from the respective FACS-purified Lym and MDM cells (Fig. 7A) . As shown in Fig. 7B , the treatment with rNef/myr significantly reduces the level of CD36 RNA transcript of approximately 40% in total PBMCs; an inhibition of 80% is observed in purified MDMs while no appreciable level of CD36 RNA is found in Lym cells. These results are reasonably concordant with the level change of CD36 membrane form expressed on rNef/myr-treated cells.
Nef Inhibits Oxidized Lipoprotein (oxLDL) Uptake MDMs
The functional relevance of Nef-induced CD36 downregulation was demonstrated by investigating the capacity to internalize oxLDL by MDMs. PBMCs were cultivated under HEMA condition w/o EPO for three days and in presence of rNef/myr for 3 additional days. Nef-induced CD36-downregulation was verified by flow cytometry analysis in cells incubated with 25 mg/ mL of DiI-conjugated native (DiI-nLDL) or oxidized LDL (DiIoxLDL). In particular we observed that LDL accumulation inside the cells increases with the incubation time regardless of the lipoprotein oxidation state (Fig. 8A) (Fig. 8B) . No significant oxLDL incorporation by lymphocytes or erythroblasts is observed (not shown). Furthermore, longer exposure time to oxLDL determines a saturation effect with a progressive reduction of the difference in lipoprotein accumulation between untreated and Nef-treated cells (not shown). This result has not been investigated yet but suggests a possible mechanism for the LDL incorporation plateau that could involve other scavenger receptors or non-specific uptake.
Nef Reduces Beads and Salmonella Tiphymurium Phagocytosis in MDMs
As a pattern recognition receptor, CD36 plays an important role in phagocytosis of several non-opsonized microbial pathogens as widely described [7] [8] [9] 41] . In order to evaluate the impairment of other MDMs functional activities by Nef-induced CD36 downregulation, we tested the ability of Nef-treated cells to internalize FITC-conjugated microparticles (0.5 mm) and nonopsonized GFP-Salmonella typhimurium (Fig. 9 ). PBMCs were cultivated under HEMA condition w/o EPO for three days and for additional 3 days in presence of rNef/myr. CD36 downregulation was verified by flow cytometry analysis before the phagocytosis assays. Phagocytosis of microparticles and bacteria measured by flow cytometry is inhibited by Nef treatment in both cases, as shown in Fig. 9A . In order to establish the role and the level of CD36 contribution in the phagocytosis, cells were preincubated with blocking antibody anti-CD36 receptor for 30 min before the phagocytosis assays. The results, shown in Fig. 9B , demonstrate that CD36 is actively involved in the uptake of both microparticles and bacteria phagocytosis. Indeed the addition of CD36 blocking antibody determines a significant reduced internalization of approximately 44% and 25% of microparticles and bacteria, respectively. These data are not dissimilar from those obtained in the presence of rNef/myr (35% and 42%, respectively). Previous reports (17, (20) (21) (22) have demonstrated that Nef induces the release of inflammatory factors including the TNF-a in MDMs. Furthermore, Boyer et al [42] have shown that this factor was able to inhibit CD36 membrane expression and the respective mRNA transcription in human monocytes. We tested the capacity of Nef to stimulate the release of TNF-a by MDMs differentiated in HEMA culture conditions w/o EPO and in M-CSF-differentiated MDMs treated with rNef/myr or infected in vitro with VSV-G pseudotyped HIV-1-expressing (Nef(+)-HIV-1) or not expressing the nef gene (DNef-HIV-1) . The results shown in Fig. 10A and B demonstrate a significant increment of TNF-a release in all the culture conditions treated with Nef (see also Table 1 ).
Therefore we determined the dose/response of recombinant human TNF-a (rhTNF-a) on CD36 expression in M-CSFdifferentiated MDMs. CD14-positive monocytes were cultivated for 5 days in the presence of M-CSF. TNF-a was added to the culture for the following three days at concentrations of 10, 3, 1 and 0.3 ng/mL. The results shown in Fig. 10C demonstrate a significant inhibition of CD36 expression induced by TNF-a although the lower concentration (0.3 ng/mL) does not produce a statistically significant effect.
Before to assess the role of TNF-a on Nef-induced inhibition of CD36 expression, we first evaluated the neutralizing capability of a polyclonal rabbit anti-human TNF-a antibody in a TNF-ainduced killing bioassay, by using the WEHI 164 cells [32] . The titration curve shown in Fig. 10D demonstrates that rhTNF-a, induced cell death down to a concentration of 0.019 ng/mL in presence of 1 mg/mL of the transcriptase blocker actinomycin D. The addition of 1 mg/mL of anti-human TNF-a antibody progressively reduced the TNF-a-induced cytotoxicity which is completely abolished at a concentration of 0.625 ng/mL (Fig. 10D) . To verify the capability of the polyclonal rabbit antihuman TNF-a antibody to neutralize the CD36 downregulation by rhTNF-a on M-CSF-differentiated MDMs, 1 mg/mL of the antibody was added to the cell culture at the same time as the rhTNF-a and incubated for additional three days. The antibody was also added every 24 h before the flow cytometry analysis.
Once again, results demonstrate the capability of TNF-a to significantly inhibit CD36 expression down to a concentration of 1 ng/mL, however this activity was abolished by the presence of anti-human TNF-a antibody (Fig. 10E) .
To understand whether TNF-a released by MDMs treated with rNef/myr could have a role in CD36 downregulation, polyclonal rabbit anti human TNF-a antibody (1 mg/mL) was added to M-CSF-differentiated MDMs at the same time as rNef/myr and incubated for additional three days. The antibody was added every 24 h before the flow cytometry analysis. The Fig. 11 shows a representative dot plot (panel A) and histogram (panel B) of M-CSF-differentiated MDMs (dot plot) and MFI of CD36 expression levels in control cells and in cells treated with two rNef/myr from different source (histogram) as identified by ''Nef'', obtained from the lab of Dr. M. Federico [22] ; and ''Nef a '', from Jena Bioscience. The level of CD36 inhibition is similar in cells treated with both the recombinant Nef proteins. In addition, as control for LPS contamination, the Nef proteins were inactivated by boiling and as shown in Fig. 11C . CD36 expression was not inhibited in cells treated with both the inactivated Nef proteins. Finally, the addition of anti-human TNF-a antibody was unable to significantly counteract the CD36 downregulation induced by Nef proteins (Fig. 11C) . Similar experiments were performed in PBMCs cultivated in HEMA culture condition w/o EPO for three days (Fig. 11D) . Recombinant human TNF-a (10 ng/mL) or rNef/myr (as experimental control) were added for additional 3 days and CD36 expression was analyzed by flow cytometry. According to previous reports CD36 expression is significantly inhibited by rhTNF-a and such inhibition is comparable to that observed in the presence of rNef/myr (Fig. 11E) . To understand the role of Nef-induced release of TNF-a in CD36 downregulation, polyclonal rabbit anti-human TNF-a antibody (1 mg/mL) was added at the same time as rNef/myr to PBMCs cultivated in HEMA condition w/o EPO culture. The antibody was added again every 24 h before the flow cytometry analysis. In Fig. 11F is shown a representative histogram in which CD36 expression in the presence of rNef/myr and anti-human TNF-a results less inhibited than in cells treated with rNef/myr only. However, this partial effect of anti-humanTNF-a antibody did not result in statistically significant reduction of the Nef effect on CD36 (Fig. 11G) .
Although some of the results here presented, and data reported in literature, suggest a possible role of TNF-a in mediating Nef activity, these last experiments would tend to exclude a possible independent experiments carried out in triplicate. (E) M-CSF-derived MDMs were treated for three days with different concentrations of rhTNF-a alone (10, 3, 1, 0.3 ng/mL) or together with anti-human TNF-a antibody (1 mg/mL). The column bar graph represent the MFI of untreated cells (Ctr CD36), TNF-a-treated cells at different cytokine concentrations (TNFa 10, 3, 1, 0.3 ng/mL) or cells incubate with both rhTNF-a and 1 mg/mL of antihuman TNF-a antibody (TNFa 10, 3, 1 ng/mL+anti TNFa) stained with FITC-conjugated anti-CD36. Matched isotype (Ctr isotype) was used as control of non-specific fluorescence signals and SYTOX Blue was used to exclude dead cells. The results (mean 6 standard deviation) are representative of three independent experiments (*p,0.05). doi:10.1371/journal.pone.0093699.g010 Table 1 . TNF-a released by MDMs. relationship between Nef-induced TNF-a release and Nefmediated CD36 downregulation.
Discussion
In the present study we highlight the effect of rNef/myr on the expression of the CD36 membrane glycoprotein. We used the HEMA culture system to expand the analysis of CD36 expression in different cell populations: erythroblasts, lymphocytes, and MDMs [34] . In particular, we found a downregulation of CD36 expression in MDMs when rNef/myr was added to the culture. We also observed that this effect was highly specific, since other macrophage markers analyzed (CD14, CD11c, CD86, CD68, CD206, TLR2 and TLR4) were not downregulated. Furthermore, despite the erythroblasts express high level of CD36 receptor as the MDM population, Nef treatment did not elicit effects suggesting a cell specific response. Because of such discrepancy, we suppose that a reduced or absent uptake of the recombinant Nef by erythroblasts occurred, although we cannot rule out the existence of a more complex molecular mechanism that might involve a different cell physiology between erythroblasts and MDMs. However, it is important to point out that Nef protein concentration of 50 ng/mL used in all the experiments is slightly higher than those observed in the blood of HIV-infected patients and SIV-infected macaques [40, 43] .
EPO, an essential component of HEMA culture, allows a massive expansion of erythroid population from PBMCs. However, we observed that removal of this factor from HEMA culture determined a significant reduced expansion of erythroblasts, favoring a relative increase of MDMs. Interesting, HEMA culture w/o EPO affects neither the phenotypic profile of MDMs nor, most important, the rNef/myr-dependent CD36 downregulation. This peculiarity allowed us to obtain a higher number of MDMs, which was helpful for carrying out better targeted analyses of the cells, in particular phagocytosis assays and RNA extraction from purified cells by FACS.
Previous reports have widely demonstrated that HIV-1 infection compromises the functionality of phagocytic cells favoring the reactivation and development of opportunistic infections during AIDS progression. The HIV-1 Nef protein, produced exclusively by Human and Simian Immunodeficiency Viruses, is considered a virus component playing a critical role in AIDS pathogenesis in HIV-infected humans. Nef influences cellular signaling pathways leading to the enhancement of viral replication, immune elusion and enhanced survival in T-cells and macrophages [12] . It also widely affects the innate immune system impairing oxidative burst response and phagocytosis in monocytes/macrophages from HIV-1 patients [14] [15] [16] . In this regard, studies on human alveolar macrophages from HIV-1 infected individuals demonstrate an impaired phagocytosis of Pneumocystis Carinii [44] that is also associated to a reduced oxidative burst response to the pathogen in vitro challenge [45] . Moreover, macrophages from HIV-1-infected patients show reduced apoptotic neutrophils phagocytosis [46] , and infected MDMs are unable in vitro to engulf pathogens as Candida albicans and Toxoplasma gondii, [47] as well as FccR and CR3 mediated phagocytosis of bacteria [48] . Mazzolini et al [49] also revealed that defect in phagocytosis in HIV-1-infected macrophages can be ascribed to a failure in focal delivery of intracellular membranes. The authors suggested that Nef protein is essential for phagocytosis inhibition, since it interacts with the AP1 complexes required for optimal phagosome formation. The overall picture that emerges from studies on the impairment of innate immune system by Nef is quite intricate. Nonetheless, the key role of Nef in this aspect of viral pathogenesis is evident. Here we report that Nef-induced CD36 downregulation in macrophage is associated to impaired scavenger activity with both significant decreased phagocytosis of fluorescent beads or GFP-producing Salmonella typhimurium, and reduced capability to internalize oxidized lipoproteins. In fact, the CD36 is a multifunctional surface receptor present on several mammalian cells and tissues. In particular it is also found on specialized phagocytes such as macrophages and on erythroid precursors [5] . Among its multiple cellular functions CD36 as scavenger receptor recognizes specific lipid and lipoprotein components of bacterial cell walls [50] , and erythrocytes infected with plasmodium falciparum [51, 52] . These functional activities generate an immune response which leads to opsonin-independent pathogen internalization.
The mechanism by which Nef downregulates CD36 expression remains elusive. The time course required by Nef to inhibit CD36 membrane expression suggests an indirect effect, probably mediated by soluble factor(s) with autocrine/paracrine activity. These data are consistent with already described observations concerning the Nef-induced release of inflammatory factors from MDMs. A previous report describes experimental evidence supporting the hypothesis that IL-10 participates to the Nefdependent inhibition of the superoxide anion (O 2
2N
) released by Figure 11 . Nef-induced TNF-a release does not explain the downregulation of CD36 expression in MDMs. Cells isolated by using CD14 magnetic beads (Miltenyi Biotec) were cultured in presence of human M-CSF (10 ng/mL) for 5 days and for additional three days in presence of two rNef/myr from different manufactures, the inactivated rNef/myr proteins by boiling or in presence of the rNef/myr proteins together with anti-human TNF-a antibody (1 mg/mL). NADPH oxidase during the respiratory burst in U937 monoblastic cell line [15] . In addition, it has been shown that Nef induces secretion of chemotactic factors from primary human monocytemacrophages, such as the CC-chemokines MIP-1a and MIP-1b [17] that correlates with the activation of AP-1, NF-kB, STAT1 and STAT3 transcription factors [19] [20] [21] [22] . With regard to a possible relationship between Nef and CD36, recent studies have reported that TNF-a inhibits both CD36 membrane and mRNA expression through a reduction of PPARc activation [42] . More recently Zamora et al. [39] have demonstrated that both TLR2 and TLR4 signals downregulate CD36 expression on peripheral blood monocytes and such inhibition is mediated by the TLRinduced cytokine TNF-a. They have also reported that LPS, Pam3CSK4 and FSL1 represent the TLR2 and TLR4 ligands able to induce CD36 downregulation. However, other factors have been described to decrease the expression of CD36. Indeed, TGFb1 and TGF-b2 inhibit the expression of CD36 by inducing phosphorylation of p44 and p42 isoforms of MAP kinase. This leads to subsequent MAP kinase-mediated phosphorylation of PPARc and, consequently, to decreased transcription of the PPARc target gene CD36 [53] . In our study we found TNF-a release in the medium by cells treated with recombinant Nef or infected with VSV-G pseudotyped HIV-1-expressing Nef. We also observed that recombinant human TNF-a added to M-CSFdifferentiated MDMs or MDMs obtained in HEMA culture condition was capable to inhibit CD36 expression. The data obtained in presence of polyclonal rabbit anti human TNF-a antibody suggest that Nef-induced TNF-a release only partially contributes to downregulation of CD36 expression in Nef-treated MDMs, although the results are not statistically significant. However, we do not definitively exclude the involvement of other intermediate factor(s) in Nef-induced CD36 downregulation and further investigation is warranted to confirm any hypothesis.
Several reports have provided evidence, both in vitro and in animal models, of the capacity of CD36 to bind and internalize OxLDL playing thus a role in atherosclerotic lesions formation [54] . Recent studies have reported that monocyte expression of CD36, whose transcription is primarily regulated by the nuclear receptor LXR, PPARc and PXR (LXR: Liver 6 receptor; PPARc: Peroxisome proliferator activated receptor c; PXR: Pregnane 6 receptor), is markedly reduced by HIV infection. In fact, the transcription of CD36 gene is impaired in monocytes and the mRNA levels significantly correlate with those of PPARc in HIV positive patients [55] . Interestingly the same authors demonstrated that HIV p17 hijacks a Rack-1/Jak-1/STAT-1 pathway in macrophages. In turn STAT-1 binds specific responsive elements on the promoter of nuclear receptors such as PPARc determining increased levels of CD36 expression [56] . Hitherto several studies have analyzed the pathogenic effects of HIV-1 involving the modulation CD36 expression in monocyte/ macrophage cells. However, discrepancies exist among many studies describing opposite effects of HIV-I on CD36 expression [55] [56] [57] [58] [59] . Two large cross-sectional studies by Feeney et al [60] and Meroni et al [61] are paradigmatic of these conflicting data in which decrease or increase of CD36 membrane expression on monocytes from HIV-positive patients compared to healthy donors are reported.
Here we describe that Nef-induced CD36 downregulation determines impairment of other scavenger activity such as reduced capability to internalize oxidized lipoproteins. This could imply repercussions for the pathogenesis of atherosclerosis and cardiovascular disease (CVD) in HIV patients [62] . Indeed, HIV infection and its pharmacological treatment are associated with dyslipidemia and increased risk of CVD. Several authors [63, 64] have observed higher levels of oxLDL in HIV-infected patients under ART. Furthermore, they have demonstrated an association between oxLDL and HIV-related lipodystrophy, suggesting that the reduction of LDL receptor levels might represent a possible cause. This hypothesis is substantiated by previous study demonstrating a lower LDL-receptor expression in lipodystrophic HIV-infected patients with respect to nonlipodystrophic HIVinfected patients [65] . Unfortunately, the in vivo implication and the role of Nef-mediated CD36 downregulation in determining or contributing to the onset of atherosclerosis and CVD are difficult to establish by the ART in HIV-infected patients. Indeed, several reports have demonstrated that ritonavir and other protease inhibitors (PIs) as part of ART alter the expression of CD36 [59, 65] .
In conclusion HIV-1 infection compromises the functionality of phagocytic cells ultimately favoring the reactivation and development of opportunistic infections during AIDS progression. The data here presented reveal for the first time that soluble rNef/myr protein dramatically reduces CD36 surface expression on MDMs. Thereby, this new Nef activity could contribute to the strategies elaborated by HIV-1 to altered pathogen disease outcomes and support the onset of opportunistic infections in HIV-1 infected people. The molecular mechanisms underlying the effects of Nefmediated CD36 downmodulation on AIDS pathogenesis are still to be fully clarified. Thus, a deeper knowledge of the mechanisms of Nef induced effects should be considered of primary importance for the development of intervention strategies and the advancement of new anti-HIV therapeutics. Unraveling factor(s) and mechanism(s) of action responsible for Nef effect might represent an exciting challenge in order to identify new pharmacological target(s) able to counteract severe opportunistic infections in HIV-1 patient amelioratating their pathologic conditions.
